Minnesmottagningen.se is the world's first digital memory clinic where individuals can go for an initial assessment of memory and other cognitive functions with the support of nurses and specialists but without having to visit the health service. From this autumn, this care will be publicly funded. This will increase the opportunity for people to have an initial assessment when there are concerns about cognitive impairment and dementia.

Capio, Sweden's largest private healthcare provider, has signed an agreement with Geras Solutions. Capio aims to make healthcare more accessible, both in digital and physical clinics. Starting in September, it will test a new care flow with the aim of supporting and relieving the care centres in the basic dementia assessment. The new flow will be made possible with the help of Capio Hemma and Geras Solutions digital tools.

Cognitive problems can have many causes. It can be the result of mental illness such as depression or fatigue syndrome. Assessment of this is part of the assessment via Minnesmottagningen.se and where it is found that further support from a psychologist is appropriate, patients can easily get support and guidance online.

Region Östergötland is testing digital support for the investigation of suspected dementia / cognitive disease. During a pilot, the region will evaluate how well digital tools can be integrated into the business and what support it provides for investigation as well as follow-up of patients.

After a successful pilot together with the health centres in Torsby and Likenäs, Region Värmland has now procured Geras Solutions' tools to support the digitalisation of dementia investigations.

Rickard Forsman and Johan Sundelöf from Geras Solutions / Minnesmottagningen .se participates in the program and talks about new digital technologies to support patients and healthcare in general to previously identify suspected cognitive impairment and dementia.

Geras Solutions was awarded the first prize in the pitch competition Life Science Battle of the Nordics during TechBBQ in Copenhagen on September 17th with the award "Most innovative Nordic startup"

The FDA has approved the biotech companyBiogen's treatment of Alzheimer's disease with adukanumab, which will be sold under the Aduhelm brand. The treatment that counteracts deposits of beet-amyloid from the brain will be the first of its kind. Demand among patients is expected to be extensive, but many challenges remain before treatment on a large scale will be considered.

Henrik Frenkel interviews Rickard Forsman and Johan Sundelöf in his podcast "Help I have Alzheimer's!?" and for his blog in Alzheimer's Life.

The study shows that the cognitive test provided by Geras Solutions via the app " Minnesmottagningen " (the memory clinic) can be a viable screening tool for cognitive impairment and dementia.

Alzheimer's Disease International (ADI) gathers a collection of associations around the world. The annual report on "From plan to Impact" ADI is reporting on the...

We welcome Niya, Mouna, Porraphun, Julio, Tyra and Padmagiri to Geras Solutions Summer Internship! The first day has been focused on getting to know each...

Vinnova awards Geras Solutions with funding for pilot and study with Region Skåne Geras Solutions have been awarded a significant grant for "Innovative Startups Phase...

Aleris and Geras Solutions have entered into an agreement to pilot and evaluate Geras Solutions digital platform for diagnostics at the health center in Bollnäs....

On March 3rd Geras Solutions filmed its contribution to "Hope in the age of dementia" at ITN Production studios in London with Sharon Thomas. The...

Geras Solutions, joins 6 other top finalists within Business Challenge Sweden's Business Development program. This year's round of Business Challenge was held at the Grand Hotel...

Geras Solutions, in collaboration with Umeå University, has conducted a research study that has recently been published in the scientific journal "Journal of Prevention of Alzheimer's Disease". The aim of the study was to establish normative data for the Geras Solutions Cognitive Test (GSCT) and to evaluate how factors such as gender and education influence the test results.